Goodwin

Partner 

Andrew Lacy is a co-chair of Goodwin’s Antitrust and Competition practice and a member of the firm’s Life Sciences Disputes group. He advises clients on transaction-related antitrust risk, negotiating terms of agreements, and determining the applicability of merger clearance filing requirements in both US and foreign jurisdictions. He represents clients before the FTC, DOJ, and state regulators in connection with informal inquiries, Second Requests, conduct investigations, and third-party subpoenas. Andrew has represented clients in merger challenges, class actions and other private antitrust litigation matters. He also provides guidance on antitrust issues related to diligence and pre-closing conduct procedures, internal compliance programs, hiring and non-compete agreements, vendor agreements, and competitor collaboration guidelines.

JD, Georgetown University Law Center 2002 / BA, American University 1997